curative treatment, they have a high frequency of HCC recurrence: [2] [3] [4] [5] [6] [7] the recurrence rate of HCC after hepatectomy is greater than 10% per year, and reaches 70%-80% after 5 years. Furthermore, almost 90% of these cases have recurrence in the residual liver. Therefore, prevention of HCC recurrence after hepatectomy is urgent.
Two major types of recurrence in HCC are known: multicentric (MC) carcinogenesis and intrahepatic metastasis (IM). MC recurrence is considered a new HCC, independent of the first HCC, and attributable to background liver disease with a high risk of carcinogenesis that relapses after a long period, later than 2 years from hepatectomy. In contrast, IM recurrence is metastasis from the primary site, which relapses earlier than 2 years after hepatectomy.
Molecular or clinical biomarkers that predict MC recurrence have
been reported, and chemoprevention drugs against the background liver disease for MC recurrence, such as antiviral drugs, have been developed. [8] [9] [10] [11] [12] Molecular signatures of MC recurrence that can predict late recurrence after hepatectomy for HCC, and molecularly targeted drugs for the chemoprevention of MC recurrence, have also been reported. [13] [14] [15] [16] [17] [18] [19] [20] However, no target gene for the molecular chemoprevention of IM recurrence has yet been identified.
In the present study, we carried out an exhaustive search to find a molecular biomarker that could predict IM recurrence and serve as a target gene for chemoprevention of IM recurrence, and discovered lysyl oxidase (LOX). LOX is a copper-dependent amine oxidase that catalyzes the final enzymatic step required for cross-linking of collagen and elastin molecules in the extracellular matrix. 21 In malignant tumors, LOX is involved in the remodeling of cancer stroma, and affects cancer metastasis or accelerates dedifferentiation of cancer cells. [22] [23] [24] High LOX expression is reportedly associated with cancer malignancy and cancer metastasis, and reflects patient prognosis in several types of cancer. [9] [10] [11] [12] [13] [14] [25] [26] [27] [28] In the context of HCC, it has been reported that high LOX expression is associated with a marker of tumor angiogenesis, but the association between LOX expression and patient outcome, especially HCC metastasis of IM, is still unclear. 28, 29 We aimed to comprehensively analyze the role of LOX in HCC by interrogating a large transcriptome database and to validate the impact of LOX expression in the recurrence of HCC from IM.
| MATERIAL S AND ME THODS

| Patients and tissue specimens
The population enrolled in the present study consisted of 358 HCC patients who underwent hepatic resection. All patients were treated at the Department of Gastroenterological Surgery, Kumamoto (strong, brown). The staining index (ranging from 0 to 9) was calculated by multiplying the score for the proportion of positive cells by that for staining intensity. Scores from 0 to 5 and from 6 to 9 defined the low and high LOX expression groups, respectively.
| Quantitative reverse transcription-polymerase chain reaction
Quantitative RT-PCR was carried out to determine LOX mRNA levels in HCC tissue cells. Total RNA was isolated from cells or tissue using Trizol (Invitrogen, Carlsbad, CA, USA), and the concentration of purified RNA was measured by comparing A 260 and A 280 using a Nanodrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA).
cDNA was generated from the total RNA using a ReverTra Ace qPCR RT kit (TOYOBO, Osaka, Japan) according to the manufacturer's instructions, and subsequently used as a PCR template. qRT-PCR was carried out as described previously. [30] [31] [32] Transcript levels were measured in a duplicate set of reactions for each gene and calculated as fold change relative to control siRNA-transfected cells.
Relative hypoxanthine phosphoribosyltransferase 1 levels were used for normalization. Sequences of primers used in this study are listed in Table S1 . 
| Cell culture
| Cell transfection
According to the manufacturer's instructions, siRNAs targeting LOX (Silencer Select siRNA, LOX, ID: s8254, s8255, s8256; Thermo Fisher Scientific, Tokyo, Japan) and hypoxia-inducible factor-1α
(HIF-1α; Silencer Select siRNA, HIF-1α, ID: s6539, s6540, s6541;
Thermo Fisher Scientific, Tokyo, Japan), and control siRNAs were transfected to the cells using Lipofectamine RNAiMAX Transfection
Reagent (Thermo Fisher Scientific, Yokohama, Japan).
Before transfection, Sk-hep1 cells were seeded to achieve 70%-80% confluence. After 24 or 48 hours of transfection, the supernatant was removed and washed with PBS twice, and RNA of Sk-hep1 cells was extracted.
| Cell Counting Kit-8 assay (growth assay)
We evaluated cell growth using a CCK-8 Kit (Dojindo Molecular
Technologies, Kumamoto, Japan) according to the manufacturer's protocols. Sk-hep1 cells were inoculated in a 96-well plate at 3.0 × 10 3 cells in 100 μL/well and the plate was incubated overnight in a humidified incubator at 37°C with 5% CO 2 . Each well of the plate also received 10 μL CCK-8 solution at the indicated time points (0, 1, 2, 3 days). Absorbance was measured at 450 nm using a microplate reader after incubating the plate for 1.5 hours. The absorbance of each sample was measured in triplicate.
| Migration and invasion assays
We carried out a migration assay of Sk-hep1 cells in six-well plates. 
| Bioinformatic and statistical analysis
Exhaustive analysis to search for target genes for IM chemoprevention and recurrence prediction was carried out using the public database GSE10141, which comprises a cohort consisting of HCC patients who underwent curative surgery and uniform follow up after surgery and includes RNA from both cancerous tissue and the adjacent background liver. Network enrichment analysis was carried out using GSEA (gene set enrichment analysis: http://software.
broadinstitute.org/gsea/index.jsp) and two other HCC public databases, GSE14520 and GSE9843, which include HCC patient samples from curative surgery. Statistical analysis was carried out using R-3.1.1 ( https://www.r-project.org/) and JMP10 (SAS, Tokyo, Japan)
programs.
| RE SULTS
| Selection of a gene that is strongly associated with early recurrence of HCC after curative surgery
As a first step toward discovering target genes for the prediction of early recurrence, we exhaustively investigated the correlation between each expressed gene and the rate of early recurrence using GSE10141, a microarray database of the cancerous area and background liver tissue of HCC cases. We analyzed the association of each gene and the rate of early recurrence within 2 years using the Cox regression model and extracted genes with a high hazard ratio (HR >3) for early recurrence to select genes that might be useful for the prediction of early recurrence and targetable genes for the prevention of early recurrence. Moreover, we extracted genes that were significantly more highly expressed in the tumor area than in the adjacent surrounding liver (P < .01 by paired t test), and selected genes that had a high hazard ratio for early recurrence and were highly expressed in the tumor area to identify candidate drug therapy targets that might work selectively against the cancer cells and not against normal liver cells. As a result, we detected LOX ( Figure 1 and Table S2 ).
| Validation of the role of LOX as a predictor of HCC recurrence from IM
We hypothesized that high LOX expression in HCC is a predictor of early recurrence, suggesting recurrence from IM, and then first validated the hypothesis using public databases. We used GSE10141 and GSE9843, which are cohorts from HCC patients and samples that underwent liver resection, and we assigned the patients into two groups based on LOX expression. We assigned the patients with the higher 25 percentile as the high LOX group, and those with the lower 75 percentile as the low LOX group. The high LOX group had a significantly high rate of early recurrence (earlier than 2 years) in both GSE10141 (P < .001) and GSE9843
(P = .026) ( Figure S1 ).
| LOX mRNA expression is higher in HCC tissue and associated with a high rate of early recurrence and poor overall survival in a validation cohort of HCC patients
To further validate the clinical role of LOX mRNA expression, we used another cohort comprising 149 HCC patients who underwent F I G U R E 1 Correlation between each gene and the rate of early recurrence using GSE10141. We searched for genes with a high hazard ratio for early recurrence to extract genes potentially useful for the prevention of early recurrence. In addition, we extracted genes that were highly expressed in the tumor area to select genes potentially useful as drug therapy targets. HCC, hepatocellular carcinoma; LOX, lysyl oxidase F I G U R E 2 A, Lysyl oxidase (LOX) expression between the tumor lesion (Tumor) and the adjacent liver tissue (Normal) measured by qRT-PCR (n = 3). B, Gene set enrichment analysis (GSEA) using the HALLMARK gene set in a transcriptome matrix from the three cohorts GSE10140, GSE14520 and GSE9843. Red color indicates a positive correlation and blue color indicates a negative correlation between LOX expression and the gene set enrichment. HCC, hepatocellular carcinoma curative hepatic resection at Kumamoto University Hospital ( Figure   S2 ). We first confirmed the expression of LOX mRNA in HCC tumor lesions and the adjacent surrounding liver tissue and found that LOX expression was significantly higher in the tumor lesion than in the adjacent liver (P < .001) (Figure 2 ).
Patients were separated based on LOX expression and grouped into a high LOX group (n = 38) consisting of patients in the higher 25% for LOX expression, and a low LOX group (n = 111) of patients in the lower 75%. The high LOX group had a significantly higher rate of early recurrence (2-year recurrence rate was 64.3% vs 42.7%, P = .024) and a worse survival rate (3-year rate was 62.7% vs 82.0%, P = .0441) than the low LOX group ( Figure S3A ). Moreover, in comparisons of clinicopathological factors between the high and low LOX groups, there were significantly more portal vein invasion (vp)-positive patients and poorly differentiated carcinoma in the high LOX group (P = .004 and .002, respectively) ( Table S3 ). Factors associated with early recurrence were also evaluated by univariate Cox regression analyses (Table S4 ). Univariate analysis showed that AFP-L3 score higher than 10 ng/mL, PIVKA-II score higher than 100 mAU/mL, multiple tumors, tumor size larger than 50 mm, Fc-positive, Fc-inf-positive, vp-positive, poorly differentiated carcinoma and high LOX expression were all significantly associated with early recurrence (P < .05).
| LOX protein expression is associated with early recurrence and overall survival in patients with HCC
To evaluate the role of LOX protein expression, TWIST protein expression and E-cadherin protein expression, we carried out IHC analysis in the Kumamoto University Hospital cohort, which included 358 patients with FFPE samples. In comparing high LOX expression and low LOX expression samples, several samples of Slug and
Vimentin were also stained ( Figure 3A) . Overall sample selection is summarized in Table S5 .
The high LOX group had a significantly higher rate of early recurrence (2-year recurrence rate was 64.0% vs 24.2%, P < .0001) and poorer survival rate (5-year rate was 60.1% vs 86.2%, P < .0001)
than the low LOX group ( Figure 3B ). Moreover, high LOX-L2 expression of the LOX family in HCC was associated with early recurrence ( Figure S4 ).
F I G U R E 3 Immunohistochemical staining of each expressed gene. A, Representative pictures of the expression of TWIST, E-cadherin (E-Cad), Vimentin and Slug in high lysyl oxidase (LOX) expression (left panels) and low LOX expression hepatocellular carcinoma (HCC) cases (right panels). B, Analyses of early recurrence rate and survival rate in the high and low LOX expression groups. C, Correlation between expression of LOX and expression of E-cadherin (left) or TWIST (right)
In addition, in comparisons of clinicopathological factors between the high and low LOX groups, there were significantly more male (P = .02), high AFP-L3 (P = .006), large tumor size (P = .03) and
Ig-positive (P = .04) patients in the high LOX group (Table 1) . Factors associated with early recurrence were also evaluated by univariate and multivariate Cox regression analyses (Table 2) . Univariate analysis showed that PIVKA-II score higher than 100 mAU/mL, multiple tumors, tumor size larger than 50 mm, poorly differentiated carcinoma, advanced hepatic fibrosis and high LOX expression were significantly associated with early recurrence. Multivariate analysis showed that PIVKA-II score higher than 100 mAU/mL (HR, 2.36; P = .025), and high LOX expression (HR, 2.52; P = .015) were independent risk factors for early recurrence.
| High LOX expression is associated with molecular EMT markers in multiple HCC patient cohorts
To identify the functional role of LOX that aggravates HCC malignancy, we carried out GSEA analysis using the HALLMARK gene set, which is the most sophisticated molecular database from MSigDB (molecular signatures database from the Broad Institute:
http://software.broadinstitute.org/gsea/msigdb), in a transcriptome matrix from the three cohorts GSE10140, GSE14520 and GSE9843 ( Figure 2 ). We found a strong association between high
LOX expression and the epithelial-mesenchymal transition (EMT)-associated gene set (EPITHELIAL_MESENCHYMAL_TRANSITION)
in all three cohorts (P < .001 in all three cohorts) as shown in Figure 2 . We also validated the correlation between LOX expression and EMT markers in the Kumamoto University Hospital cohort by IHC staining and qRT-PCR. High LOX expression was significantly associated with high TWIST expression at the protein and mRNA levels (P < .0001 and .04, respectively), and with low E-cadherin protein expression (P < .0001) ( Figure 3C and Figure S3B ).
Vimentin and Slug expression was significantly high in high LOX
expression group compared to low LOX expression group at the protein level.
| Assessment of the factors upstream of LOX in multiple HCC cohorts
Considering the factors upstream of LOX, it has been reported that HIF-1α or hypoxia activates LOX expression in colon cancer and regulates distant metastasis. 33 We therefore next assessed the association between LOX expression and the expression of HIF-1α or hypoxia-related genes.
We selected the molecular gene sets from MSigDB ( http:// software.broadinstitute.org/gsea/msigdb) and analyzed the association among these molecular gene sets and LOX expression by GSEA in the transcriptome matrix of four HCC cohorts, Figure S5 shows the results of LOX mRNA expression in each cell line by qRT-PCR. We selected Sk-hep1 for the in vitro knockdown experiment because of the high LOX expression of Sk-hep1 cells.
| LOX regulates TWIST-induced EMT which is regulated by the HIF-1α pathway
Furthermore, siRNAs targeting LOX and targeting HIF-1α adequately knocked down LOX and HIF-1α mRNA expression, respectively suggesting that the si RNAs works correctly. Figure 5A shows the movement of cells in each well and quantification of the moving distance. When the knockdown of LOX or HIF-1α by RNA interference was applied to the Sk-hep1 cell line, the migratory capability was significantly decreased as compared with control (siLOX; P = .014, .017, siHIF-1α; P = .013, .028) ( Figure 5A ).
In the invasion assay, when we applied the knockdown of LOX or HIF-1α by RNA interference to the Sk-hep1 cell line, the invasion capability was significantly decreased as compared with control (siLOX; P = .02, <.001, siHIF-1α; P < .001) ( Figure 5B ). In the CCK-8 assay, cell proliferation of Sk-hep1 was not significantly suppressed by the knockdown of LOX or HIF-1α compared with control (siLOX; P = .30, .37, siHIF; P = .13, .49) ( Figure S6A ). Furthermore, there was no morphological change in the knockdown of LOX or HIF-1α
( Figure S6B ). Figure 5C shows the expression change of the EMT markers when we knocked down LOX or HIF-1α, or both LOX and HIF-1α.
Message level of LOX expression was suppressed when LOX or HIF-1α were knocked down (all, P < .001). Conversely, knocking down of LOX did not suppress HIF-1α expression (P = .33), suggesting that HIF-1α is upstream of LOX. Furthermore, TWIST expression and Vimentin were suppressed by knocking down either LOX or HIF-1α or both LOX and HIF-1α (TWIST; P = .04, P = .01, P = .005, Vimentin; P = .05, P = .02, P = .04). Slug expression was significantly suppressed by the knockdown of HIF-1α (P = .04) and tended to be suppressed by LOX or both LOX and HIF-1α knockdown (P = .053, P = .14). 
| D ISCUSS I ON
In the present study, by searching a large transcriptome database exhaustively, we identified LOX as a key molecule associated with early HCC recurrence within 2 years; this may be due to IM. We also validated the clinical role of LOX as a predictor of HCC recurrence from IM in an independent HCC cohort, and found that LOX is clinically associated with EMT markers and the HIF-1α/hypoxia cascade.
In HCC, early recurrence caused by IM has been a major prob- 
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